Paper Details

  1. Home
  2. Paper Details

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.

Author: DreyerRichard F, KokameGregg T, ShapiroHoward, StollerGlenn L, TuomiLisa L

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In patients with neovascular age-related macular degeneration, improvement of 15 letters or more from baseline occurred in 25.2% of patients within 3 months of beginning ranibizumab treatment, whereas an additional 13.7% achieved this gain by 12 months. PRN treatment with monthly monitoring was effective in maintaining early vision gains and allowing delayed vision gains.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Understanding the range of temporal responses to ranibizumab is critical for the assessment of individualized treatment regimens for neovascular age-related macular degeneration. OBJECTIVE: To examine patterns of visual and anatomical response to ranibizumab treatment. DESIGN, SETTING,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1001/jamaophthalmol.2016.0379

データ提供：米国国立医学図書館（NLM）

Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Neovascular age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. Ranibizumab is a medication that is injected into the eye to treat AMD. This study examined the patterns of visual and anatomical response to ranibizumab treatment, looking at how quickly and effectively the treatment improves vision. Imagine a camel caravan facing a desert mirage - some travelers might see a clear path to recovery, while others might take longer to reach the oasis.

Early vs. Delayed Response to Ranibizumab Treatment

The researchers found that some patients experienced a rapid improvement in their vision within three months of starting treatment, while others saw a slower improvement, taking up to a year to reach a significant level of vision gain. This suggests that the response to ranibizumab treatment can vary widely among individuals. The study also found that patients who responded quickly to treatment continued to maintain those gains over time, even when they were treated on an as-needed basis, rather than with monthly injections.

Navigating the Desert of Vision Loss

This research provides valuable insights into the individual variability in response to ranibizumab treatment for AMD. It highlights the importance of careful monitoring and adjusting treatment plans based on each patient's unique needs. Just as a camel guide adapts its route to the changing desert landscape, doctors must be adaptable in their approach to treating AMD, ensuring that patients receive the best possible care.

Dr.Camel's Conclusion

This study provides a detailed look at the range of visual and anatomical responses to ranibizumab treatment for AMD. It emphasizes the importance of personalized treatment strategies, tailored to each patient's unique needs and response to therapy. Just as a camel caravan traverses a desert landscape, navigating diverse terrain and adapting to changing conditions, doctors must be prepared to adjust their approach to treatment based on the individual patient's journey.

Date :
  1. Date Completed 2017-05-02
  2. Date Revised 2019-04-12
Further Info :

Pubmed ID

27010625

DOI: Digital Object Identifier

10.1001/jamaophthalmol.2016.0379

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.